Scarica l'app Stockscreener
4.65
3.73%
-0.18
Dopo l'orario di chiusura:
4.65
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ATRA Giù?
Forum
Previsione
Atara Biotherapeutics Inc Borsa (ATRA) Ultime notizie
ROSEN, A TOP RANKED LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in ... - Bluefield Daily Telegraph
ROSEN, A TOP RANKED LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors - GlobeNewswire
ATRA Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Atara ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, - GlobeNewswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit ... - Caledonian Record
ATRA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Atara Bioth - GuruFocus
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - PR Newswire
2026-04-10 | ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse
ROSEN, A LEADING NATIONAL FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph
ROSEN, A LEADING NATIONAL FIRM, Encourages Atara - GlobeNewswire
ROSEN, A LEADING NATIONAL FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman LLC Urges Atara - GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain OfficersATRA - PR Newswire
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Robbins LLP Urges ATRA Stockholders Who Lost Money Investing in Atara Biotherapeutics, Inc. to Contact The Firm For Information About Leading The Class Action - ACCESS Newswire
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Atara Biotherapeutics Investors Face Deadline - National Today
Atara Biotherapeutics Investors Have Until May 22 to Seek Lead Plaintiff Role - National Today
ATRA INVESTOR REMINDER: Atara Biotherapeutics, Inc. - GlobeNewswire
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money H - GuruFocus
ATRA Shareholder Alert: May 22, 2026 Lead Plaintiff Deadline in - GuruFocus
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ATRA Shareholder Alert: May 22, 2026 Lead Plaintiff Deadline in Atara Biotherapeutics, Inc. Securities Class Action Lawsuit — The Gross Law Firm - Morningstar
ATRA Stock Price, Quote & Chart | ATARA BIOTHERAPEUTICS INC (NASDAQ:ATRA) - ChartMill
ROSEN Law Firm Encourages Atara Biotherapeutics Investors to Seek Legal Counsel - National Today
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure ... - Caledonian Record
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Atara - GlobeNewswire
Risk Analysis: What analysts say about Atara Biotherapeutics Inc stockWeekly Investment Summary & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Shareholders that lost money on Atara Biotherapeutics, - GlobeNewswire
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) - GlobeNewswire
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
2026-04-05 | ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse
Atara Biotherapeutics, Inc. (ATRA) registers possible resale of 400K common shares tied to HCR warrant exercise - MSN
Securities Fraud Investigation Into Atara Biotherapeutics, Inc - The National Law Review
ATRA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit - Lelezard
ATRA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - Sahm
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure ... - Black Hills Pioneer
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, I - GuruFocus
ROSEN Counsel Encourages Atara Biotherapeutics Investors to Act - National Today
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Atara - GlobeNewswire
ATRA SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on - GlobeNewswire
ATRA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds - GuruFocus
ATRA Technical Analysis & Stock Price Forecast - Intellectia AI
ATRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise - Yahoo Finance
Aug Sectors: Is Atara Biotherapeutics Inc being accumulated by smart moneyWeekly Profit Report & Smart Investment Allocation Tips - baoquankhu1.vn
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - WFMZ.com
DEADLINE ALERT for LU, ATRA, and COTY: The Law Offices of - GlobeNewswire
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Deadline Approaching: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith - ChartMill
Atara Biotherapeutics Faces Class Action Lawsuit - Intellectia AI
ATRA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors ... - Bluefield Daily Telegraph
Atara Biotherapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before May 22, 2026 to Discuss Your RightsATRA - marketscreener.com
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx - GlobeNewswire Inc.
2026-04-01 | ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse
Did You Lose Money Investing in Atara Biotherapeutics, - GlobeNewswire
Pomerantz Law Firm Files Class Action Against Atara Biotherapeutics - National Today
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics Lawsuit - National Today
0.95%
3.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):